Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - Indicator of endothelial dysfunction and reduced fibrinolytic capacity

European Journal of Clinical Investigation

Volumn 28, Issue 12, 1998, Pages 1050-1054

  Li, Y ^a,b   Chen, H ^a   Tan, J ^a   Wang, X ^a   Liang, H ^a   Sun, X ^a  

^a ZUNYI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Endothelial dysfunction; Fibrinolytic activity; Hyperthyroidism; Plasminogen activator inhibitor 1; Tissue plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; RADIOACTIVE IODINE; THYROID HORMONE; THYROXINE; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; FIBRINOLYSIS; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MALE; PRIORITY JOURNAL; THYROID HORMONE BLOOD LEVEL; THYROXINE BLOOD LEVEL; VASCULAR ENDOTHELIUM;

ADULT; ENDOTHELIUM, VASCULAR; FEMALE; GRAVES DISEASE; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 0032449114     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00381.x     Document Type: Article

References (29)

1. 1 Simone JV, Abildgaard CF, Schulman I. Blood coagulation in thyroid dysfunction. N Engl J Med 1965; 273: 1057-61.
2. 2 Edson JR, Fecher DR, Doe RP. Low platelet adhesiveness and other haemostatic abnormalities in hypothyroidism. Ann Intern Med 1975; 82: 342-6.
3. 3 Takahashi H, Yamada M, Shibata A. Acquired von Willebrand's disease in hyperthyroidism. Thromb Haemost 1987; 58: 1059.
4. 4 Rogers IIJS, Shane SR, Jencks FS. Factor VIII activity and thyroid function. Ann Intern Med 1982; 97: 713-6.
5. 5 Dalton RG, Dewar MS, Savidge GF et al. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet 1987; ii: 1007-9.
6. 6 Liu L, Wang X, Lin Z, Wu H. Elevated plasma levels of vWF:ag in hyperthyroidism are mediated through beta-adrenergic receptors. Endocrine Res 1993; 19 (2 and 3): 123-33.
7. 7 Rogers IIJS, Shane SR. Factor VIII. activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983; 102: 444-9.
8. 8 Jensen T, Knudsen JB, Rasmussen BF, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989; 1: 461-3.
9. 9 Berg MVD, Boers GHJ, Franken DG et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176-81.
10. 10 Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15: 1114-20.
11. 11 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-30.
12. 12 Laurell C. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52.
13. 13 Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma as studied by an improved enzyme-liked immunosorbent assay. Clin Chem 1986; 32: 2160-5.
14. 14 Dederck PJ, Aless M.-C, Verstreken M, Kruithof EKO, Juhan-Vague I., Collen D. Measurement of plasminogen activator inhibitor-1 in biologic fluids with a murine monoclonal antibody - Based enzyme-linked immunosorbent assay. Blood 1988; 71 (1): 220-5.
15. 15 Smith RS, Auger MJ. Hypothyroidism and von Willebrand's disease. Lancet 1987; ii: 1314.
16. 16 Baumgartner-parzer SM, Wagner L, Reining C et al. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997; 154: 231-9.
17. 17 Petersen KR, Skouby SO, Sidelmann J, Jespersen J. Assessment of endothelial function during oral contraception in women with insulin-dependent diabetes mellitus. Metabolism 1994; 43: 1379-83.
18. 18 Stehouwer CDA, Nuatta JJP, Zeldenrush GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non- insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
19. 19 Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary disease. Br Med J 1985; 291: 573-4.
20. 20 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
21. 21 Nakayama M, Yamada K, Yamamoto Y et al. Vascular endothelial dysfunction in patients on regular dialysis treatment. Clin Nephrol 1994; 42: 117-20.
22. 22 Graninger W, Pirich KR, Speiser W, Deutsch E, Waldhäusl WK. Effect of thyroid hormones on plasma protein concentration in man. J Clin Endocrinol Metab 1986; 63: 407-11.
23. 23 Rennie JA, Bewsher PD, Murchison LE, Ogston D. Coagulation and fibrinolysis in thyroid disease. Acta Haematologica 1978; 59: 171-7.
24. 24 Farid NR, Griffiths RL, Collins JR, Marshall WH, Ingram DW. Blood coagulation and fibrinolysis in thyroid disease. Thromb Haemost 1976; 35: 415-22.
25. 25 Marongiu F, Conti M, Mameli G et al. Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. J Endocrinol Invest 1988; 11: 723-5.
26. 26 Marongiu F, Conti M, Murtas ML, Mameli G, Sorano GG, Martino E. Activation of blood coagulation and fibrinolysis in Graves' disease. Horm Metab Res 1991; 23: 609-11.
27. 27 Gaffney PJ, Longstaff C. An overview of fibrinolysis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis, 3rd edn. Edinburgh: Churchill Livingstone 1994: 549-73.
28. 28 Juhan-Vague I, Allesi MC, Fossat C, Valadier J, Aillaud MF Serradimigni A. Clinical relevance of reduced t-PA release upon venous occlusion in patients with idiopathic/recurrent deep vein thrombosis. Fibrinolysis 1988; 2 (Suppl. 2): 112-3.
29. 29 Presti CF, Hart RG. Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 1989; 117: 976-7.